Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNCT19 CAR-T Therapy in Advanced Hepatocellular Carcinoma
NCT06676982Phase 1Recruiting
- Sponsor
- Zhejiang University
- Start
- Jan 2025
- Primary completion
- Jul 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of inaticabtagene autoleucel in hepatocellular carcinoma (HCC), sponsored by Zhejiang University. Primary endpoints: Dose Limiting Toxicity at 28 days, Adverse Events at 24 months and 1 more. Started Jan 2025; status: recruiting.
02
Drugs
inaticabtagene autoleucel
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06676982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06676982.